^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SLAMF7 FPBMC

    i
    Other names: SLAMF7 FPBMC, SLAMF7 BATs/CS-1 BATs, anti-CD3 x anti-SLAMF7 bispecific antibody armed activated T cells
    Associations

    News

    Trials
    Company:
    University of Virginia
    Drug class:
    CS-1 inhibitor, CD3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    MM FPBMC: Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, University of Virginia
    Trial completion date • Trial primary completion date
    |
    SLAMF7 (SLAM Family Member 7)
    |
    SLAMF7 FPBMC
    6ms
    MM FPBMC: Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, University of Virginia | N=18 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    SLAMF7 (SLAM Family Member 7)
    |
    SLAMF7 FPBMC
    10ms
    MM FPBMC: Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2; Trial completion date: Jan 2030 --> May 2030 | Trial primary completion date: Jan 2027 --> May 2027
    Trial completion date • Trial primary completion date
    |
    IFNG (Interferon, gamma) • SOX2 • SLAMF7 (SLAM Family Member 7)
    |
    clonoSEQ
    |
    SLAMF7 FPBMC
    1year
    MM BATs: Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2; Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 | Trial completion date: Jun 2028 --> Jan 2030 | Trial primary completion date: Jun 2027 --> Jan 2027
    Trial completion date • Trial primary completion date • Phase classification • Enrollment open
    |
    IFNG (Interferon, gamma) • SOX2 • SLAMF7 (SLAM Family Member 7)
    |
    clonoSEQ
    |
    SLAMF7 FPBMC
    2years
    MM BATs: Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1; Trial completion date: Jan 2027 --> Jun 2028 | Trial primary completion date: Jan 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    IFNG (Interferon, gamma) • SLAMF7 (SLAM Family Member 7)
    |
    clonoSEQ
    |
    SLAMF7 FPBMC
    3years
    MM BATs: Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1; N=25; Not yet recruiting; Sponsor:University of Virginia
    New P1 trial • Clinical
    |
    IFNG (Interferon, gamma) • SLAMF7 (SLAM Family Member 7)
    |
    clonoSEQ
    |
    SLAMF7 FPBMC